Kurve Therapeutics, a transformative dementia and Alzheimer’s treatment company, launches a $50 million crowdfunding round

0

Blood-brain barrier

Shari Noonan, CEO of Rialto Markets

Next-generation medical technology innovator Kurve Therapeutics is embarking on a crowdfunding journey with its $50 million raise under A+ regulations.

Kurve Therapeutics’ intranasal drug delivery technology has the potential to transform the lives of millions of people with neurodegenerative diseases.”

— Shari Noonan, CEO of Rialto Markets

NEW YORK, NEW YORK, USA, Sept. 14, 2022 /EINPresswire.com/ — Transformative dementia and Alzheimer’s disease treatment company Kurve Therapeutics launches $50 million fundraiser

Next-generation medical technology innovator Kurve Therapeutics is embarking on a crowdfunding journey with its $50 million raise under A+ regulations.

Private investors can now invest in a venture aimed at disrupting and transforming a $1.3 trillion dementia market alone while benefiting millions of people living with neurodegenerative diseases.

Diseases such as dementia and Alzheimer’s disease affect millions of people worldwide, while more than one billion people worldwide – 1 in 6 – suffer from a neurological disease. Yet healthcare sectors lack effective, disease-modifying treatments.

Kurve Therapeutic’s patented intranasal drug delivery technology, Controlled Particle Dispersion® (CPD), has been shown to bypass the blood-brain barrier, delivering 30 times more drugs directly to the brain than infusions.

Marc Giroux, CEO and Founder of Kurve Therapeutics, said: “An intravenous infusion manages to deliver a tenth of 1% across the blood-brain barrier. We have measured our success at 30 times more than that. This is not an insignificant achievement.

“Central nervous system disorders are a scourge because they are difficult to treat by their very nature. We have the potential to eliminate this problem, so that an unmet need becomes a met need,”

Giroux now hopes to propel Kurve Therapeutics into a new period of growth, by partnering with award-winning broker-dealer Rialto Markets’ crowdfunding infrastructure and technology for its A+ regulatory offering:

“After extensive work developing treatments and our CPD technology, we are ready to scale the business and grow our investor community.

“We plan to invest most of our profits in our final Phase III clinical trials of intranasal insulin for mild cognitive impairment in Alzheimer’s disease. Kurve Therapeutics is ready for Phase III clinical trials in three distinct disease states and is one Phase III study away from being eligible. for FDA approval.”

Shari Noonan, CEO and Co-Founder of Rialto Markets, said, “Kurve Therapeutics’ intranasal drug delivery technology has the potential to transform the lives of millions of people suffering from neurodegenerative diseases.

“This is a very exciting and important industry that needs this essential innovation, so we are delighted that Kurve Therapeutics has chosen to work with us to grow and evolve.

Rialto Markets has a capital raising infrastructure for the Reg CF and Reg A+ crowdfunding as well as the Reg D institutional investment offering. Along with this, Rialto Markets has an alternative trading system on the pioneering secondary market (ATS) that allows the buying and selling of private company shares or other private securities, which can operate in the same manner in a regulated setting and environment as a stock exchange like the Nasdaq does and NYSE for public company trading.

This secondary trading ATS allows private companies and shareholders to potentially create liquidity and trade within a $7 trillion private securities market that is expected to grow to $30 trillion by 2030, potentially enabling better access to vital financing and private securities in a fully regulated environment.

Ends
_________________________________________________________________
Rialto Markets is a FINRA member broker (Primary Rialto) and operates an alternative trading system (Secondary Rialto – Rialto MarketBoard™) for private securities, including those issued as a digital asset security. Rialto Primary supports companies issuing equity and debt securities through the Reg A+, Reg CF and Reg D exemptions. Rialto Markets is registered in all 50 states, including those that require a broker-dealer to issue Reg A+

Kurve Therapeutics Led by a team of experienced entrepreneurs with proven track records in biotechnology, pharmaceuticals and device technology, our mission is to lead the way in the treatment of complex CNS disorders, including the disease Alzheimer’s, cognitive aging, dementia with Lewy bodies, Parkinson’s disease and ALS. Kurve technology is featured in 18 peer-reviewed publications in leading medical journals. The Kurve technology has been used in five double-blind, placebo-controlled Phase II studies and is ready for Phase III with patients with Alzheimer’s disease.

steve philippe
Global Digital Foundation
07973159065
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Share.

Comments are closed.